All
Steroid-free atopic dermatitis topical completes phase 4 trial
July 2nd 2019Crisaborole ointment, 2%, (Eucrisa, Pfizer) appears to be safe and effective in children aged three months to less than 24 months who have mild-to-moderate atopic dermatitis, according to results of a phase 4 trial released yesterday.
Reflections on the 40th Anniversary of Dermatology Times
July 1st 2019To celebrate the 40th Anniversary of Dermatology Times, we asked our Editorial Advisory Board members to reflect on the publication and how the practice of dermatology has changed over the past 40 years. In this article, Dr. Wheeland reviews his years of involvement with the Dermatology Times and what has happened in the dermatologic surgery world over those same years.
Does FDA have jurisdiction over my comments?
June 26th 2019The Food, Drug and Cosmetic Act (FDCA) gives the U.S. Food and Drug Administration (FDA) the authority to ensure that drug/device promotion is not false and/or misleading. But does that mean the FDA can regulate physician comments on drugs and devices? Dr. Goldberg provides his insight in this month's Legal Eagle column.
Psychodermatology: Where the skin and mind meet
June 26th 2019This article is the first of our series on psychodermatology from Gina M. Caputo, D.O. In it, she highlights the prevalence of emotional disorders in patients with skin diseases, and introduces the four main classifications of psychodermatological disorders.
What you should know about technology transfer
May 10th 2019In this month's Innovations column, Steve Xu, M.D., FAAD, begins the first part of a two-part mini-series discussing what innovators should know about intellectual property. This installment focuses on the different scenarios innovators may run into when dealing with the transfer of technological property, called technology transfer.